Meeting
2014 Genitourinary Cancers Symposium
Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
Authors
Ravi Amrit Madan
Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD
Ravi Amrit Madan , Kwong Yok Tsang , Caroline Jochems , Jennifer L. Marte , Jo A Tucker , James W. Hodge , Harpreet Singh , Ira Surolia , Geraldine Helen O'Sullivan Coyne , David J. Liewehr , Seth M. Steinberg , Christopher Ryan Heery , Jeffrey Schlom , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer
Clinical Trial Registration Number
multiple trials
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 245)
DOI
10.1200/jco.2014.32.4_suppl.245
Abstract #
245
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.
First Author: Giulio Francolini
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Douglas G. McNeel
Poster
2017 Genitourinary Cancers Symposium
Indomethacin to inhibit AKR1C3 intracrine androgen production and sensitizes prostate cancer (PCa) to enzalutamide.
First Author: Chong-xian Pan